Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that an early-stage compound with a novel mechanism of action could potentially treat all dengue virus...
AstraZeneca’s Alexion will fully acquire the remaining equity in Caelum Biosciences for the company’s first-in-class fibril-reactive monoclonal antibody (mAb) to treat rare disease light...
Johnson & Johnson recently submitted data to the FDA to support its COVID-19 vaccine booster shot in adults 18 and older.
The submission includes results from the Phase 3 ENSEMBLE study, which...
Johnson & Johnson recently initiated a Phase 3 clinical trial to study its RSV vaccine's efficacy, safety, and immunogenicity against lower respiratory tract disease (LRTD) in adults.
The...
AstraZeneca recently submitted a request to FDA for an emergency use authorization for its long-acting COVID-19 antibody combination, AZD7442.
AstraZeneca optimized AZD7442 using its YTE half-life...
Johnson & Johnson recently announced that Xarelto elicited fewer blood clots and clinical events strongly associated with blood clots in pediatric patients compared to treatment with aspirin.
The...
Regeneron recently announced that its COVID-19 antibody cocktail, REGEN-COV, significantly reduced viral load in patients hospitalized with the coronavirus.
The trial enrolled 1,197 patients to...
Pfizer and BioNTech recently submitted data to FDA from the Phase 2/3 clinical trial of their COVID-19 vaccine in children five to 11 years of age.
Last week, the companies announced that...
FDA recently approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Value to improve therapy options for individuals with mitral or aortic valve disease.
The next-generation devices...
Pfizer recently announced the start of a Phase 2/3 study to evaluate its COVID-19 treatment in combination with ritonavir to prevent coronavirus disease.
The randomized, double-blind EPIC-PEP study...
Roche recently announced that Tecentriq elicited disease-free survival in patients with Stage II-IIA non-small cell lung cancer (NSCLC).
Data from the IMpower010 trial, published in The Lancet, found...
SAS and the University of North Carolina at Chapel Hill (UNC-Chapel Hill) recently partnered to transform the antiviral drug development process and prevent infectious disease threats from turning into...
FDA recently amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to allow for a single booster dose six months after completing the primary series.
In December 2020,...
Johnson & Johnson recently announced that a booster shot of its COVID-19 vaccine elicited 94 percent protection against coronavirus in a Phase 3 clinical trial.
The largest real-world...
Johnson & Johnson recently announced that its Ebola vaccine regimen, Zabdeno and Mvabea, generated robust antibody immune responses in children and adults.
The Phase 3 EBOVAC-Salone clinical...
FDA recently granted Breakthrough Designation for Eli Lilly & Company and Boehringer Ingelheim’s diabetes drug, Jardiance, as an investigational treatment for adults with heart failure with...
Pfizer and BioNTech recently announced that two doses of their COVID-19 vaccine elicited neutralizing antibody responses in pediatric patients in a Phase 2/3 clinical trial.
In the trial,...
National Resilience recently entered into a multi-year agreement with Moderna to manufacture drug substance mRNA for its COVID-19 vaccine.
Resilience is a manufacturing and technology company...
Pfizer recently initiated a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus (RSV) vaccine candidate in adults.
The...
